
ADC Therapeutics (ADCT) Stock Forecast & Price Target
ADC Therapeutics (ADCT) Analyst Ratings
Bulls say
ADC Therapeutics is supported by ZYNLONTA’s commercial approval, which reduces regulatory risk and provides tangible cash flows, while its demonstrated efficacy strengthens physician adoption and the potential for broader use across indications. The company also has optionality in additional indolent lymphomas, and the cited capital raise in 4Q25 gives it a cash runway until 2028, which appears sufficient to fund execution of its likely expansion into earlier lines of treatment. With the U.S. as the largest revenue contributor and Europe, the Middle East and Africa next, the geographic footprint adds further commercial leverage to the positive outlook.
Bears say
ADC Therapeutics is facing a weaker fundamental profile because ZYNLONTA’s confirmatory LOTIS-5 data showed only a modest PFS gain (HR 0.73) with no OS benefit (HR 0.96) and an elevated Grade 5 TEAE rate, prompting FDA “substantial concerns” about benefit-risk and verification of clinical benefit. The company’s 2Q net sales of $18.6M were only stable rather than accelerating, and while it ended the quarter with $219M in cash and said runway extends at least into 2028, that liquidity cushion does not offset the growing regulatory overhang or the risk that 2L+ DLBCL adoption remains limited. Although management outlined a $10M annualized cost reduction and continued development plans for LOTIS-7 and other programs, the stock faces reduced approval probability, slower revenue ramp assumptions, and a more uncertain competitive position in a crowded lymphoma market.
This aggregate rating is based on analysts' research of ADC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction
Start investing in ADC Therapeutics (ADCT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ADC Therapeutics (ADCT) Forecast
ADC Therapeutics (ADCT) Analyst Forecast & Price Prediction
Start investing in ADC Therapeutics (ADCT)
Order type
Buy in
Order amount
Est. shares
0 shares